Geographic Atrophy From Age-related Macular Degeneration Clinical Trials
2 recruiting trials for Geographic Atrophy From Age-related Macular Degeneration. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Geographic Atrophy From Age-related Macular Degeneration clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
The only sponsor on record for these trials is Ray Therapeutics, Inc. (2 trials).
Track Geographic Atrophy From Age-related Macular Degeneration trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited...
The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The...
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal...
The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Geographic Atrophy From Age-related Macular Degeneration, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Geographic Atrophy From Age-related Macular Degeneration, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Geographic Atrophy From Age-related Macular Degeneration, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.